Cardinal Health (CAH) Q3 2026 earnings review
Guidance Raised on Core Strength, but GAAP Earnings Marred by Impairment and Tariffs
Cardinal Health continues to ride the momentum of its Pharmaceutical and 'Other' growth segments, driving a 35% YoY increase in Non-GAAP EPS and prompting a third consecutive raise to FY26 EPS guidance (now $10.70-$10.80). However, the GAAP results reveal notable cracks in the armor. Operating earnings fell 30% YoY due to a sudden $184M goodwill impairment in the Navista & ION unit, while the Global Medical Products and Distribution (GMPD) segment saw profit plunge 36% under the weight of tariffs. Despite the top-line deceleration from H1, the company's core profit engine remains highly robust.
🐂 Bull Case
The Pharmaceutical and Specialty Solutions segment continues its dominant run, with segment profit accelerating to 18% YoY growth ($784M) driven by brand and specialty products and positive generics program performance.
Non-GAAP operating earnings grew 18% despite revenue decelerating to 11%. Management confidently raised FY26 profit growth outlooks for both the Pharma (22-23%) and Other (36-38%) segments.
🐻 Bear Case
The GMPD segment remains a liability. With revenue flat, segment profit collapsed 36% YoY to $25M. The adverse net impact of tariffs is severely compressing margins in this division.
A $184M pre-tax goodwill impairment in the Navista & ION unit indicates that recent acquisitions face higher risk profiles and potential base operational underperformance, challenging the company's aggressive M&A narrative.
⚖️ Verdict: 🟢
Bullish. While the GMPD weakness and the ION impairment are clear blemishes, the sheer scale and profitability of the Pharmaceutical segment, combined with rapid growth in the 'Other' businesses, provide a massive buffer that easily supports the raised FY26 outlook.
Key Themes
Navista & ION Goodwill Impairment
A significant red flag emerged regarding recent M&A execution. Cardinal took a $184M pre-tax goodwill impairment in its Navista & ION reporting unit. Management cited 'changes in the risk profile of the business plans resulting in an increase in the discount rate' and 'base operational performance.' This contradicts the previously pristine narrative surrounding their aggressive expansion into Specialty MSO platforms.
GMPD Segment Collapsing Under Tariffs
The GMPD segment turnaround has reversed sharply. Segment profit fell 36% YoY to $25M in Q3, down sequentially from $37M in Q2, $46M in Q1, and $70M in 25Q4. Management explicitly blamed the 'adverse net impact of tariffs.' With revenue flat YoY, the segment is losing operational leverage.
Unstoppable Momentum in 'Other' Growth Businesses
The 'Other' segment (Nuclear and Precision Health Solutions, at-Home Solutions, OptiFreight Logistics) is accelerating. Revenue surged 31% YoY to $1.7B, and segment profit grew 34% to $179M. The integration of Advanced Diabetes Supply (ADS) is bearing fruit, and secular tailwinds in home health and theranostics remain incredibly strong.
Pharmaceutical Margins Expanding
The core Pharmaceutical and Specialty Solutions segment continues to outperform. While revenue growth decelerated to 11% (from 19% in Q2), segment profit grew 18% to $784M. This indicates excellent margin management, driven by a favorable mix shift toward brand and specialty products alongside consistent generics program performance.
Disciplined Capital Allocation and Deleveraging
Despite a heavy M&A load, Cardinal Health is aggressively managing its balance sheet. The company completed a $100M term loan payment ahead of schedule, lowering its leverage ratio to 3.0x (comfortably within its 2.75x-3.25x target). Concurrently, it executed an additional $250M share repurchase, bringing the FY26 year-to-date total to $1.0B.
Actinium-225 Production Capability
Innovation in radiopharmaceuticals is a key differentiator. The company announced a significant expansion of Actinium-225 (Ac-225) production capabilities at its Indianapolis Center for Theranostics Advancement. This addresses a critical supply chain bottleneck for investigational and future commercial novel therapeutic drug products.
Other KPIs
Accelerating significantly compared to $1.184B in the prior year-to-date period. This massive cash generation is funding the share repurchase program and rapid deleveraging, giving management the confidence to raise the full-year adjusted free cash flow guidance to $3.3B-$3.7B.
Plummeted from 22.4% in 25Q3, primarily due to 'discrete planning benefits.' This structurally lower tax rate was a significant tailwind for the 35% growth in Non-GAAP EPS during the quarter, allowing management to reduce the full-year tax rate guidance to approximately 19%.
Guidance
Accelerating. Raised and narrowed from the Q2 guidance of $10.15-$10.35. This implies a 30% to 31% YoY growth rate. The upgrade is driven by improved operating segment performance, a lower expected share count (~237M), and a lower effective tax rate.
Accelerating. Raised from the prior range of 20% to 22%, signaling immense confidence in specialty distribution margins and generics performance for the final quarter.
Accelerating. Raised from the prior range of 33% to 35%, reflecting durable outperformance in Nuclear, at-Home, and OptiFreight logistics.
Key Questions
Navista & ION Impairment Mechanics
Can you detail the specific 'changes in the risk profile' and base operational underperformance that triggered the $184M goodwill impairment in the Navista & ION unit so soon after the acquisition? Does this alter your underwriting assumptions for future MSO acquisitions like Solaris?
GMPD Tariff Floor
GMPD segment profit has deteriorated sequentially for three straight quarters, landing at $25M in Q3. Is this the trough for the tariff impact, or should we expect further margin compression in Q4?
Tax Rate Sustainability
The Q3 Non-GAAP effective tax rate dropped to 10.2% due to discrete planning benefits, lowering the full-year guide to ~19%. How much of this benefit is structural versus a one-time true-up, and how should we model the tax rate moving into FY27?